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Abstract
Background: T cells from HIV+ and aged individuals show parallels in terms of suppressed proliferative activity
and interleukin-2 (I1-2) production and an increased number of CD8+ CD28- T cells. In order to compare
cytokine production from T cells from these two states, CD4+ and CD8+ T cells from HIV+ aged, and normal
young donors (controls) were monitored for cytokine production by flow cytometry, quantitative PCR and ELISA
upon activation by PMA and anti-CD3. In addition, the CD8+ T cell subsets CD28+ and CD28- from the HIV+
and the aged groups were evaluated for cytokine production by flow cytometry, and compared with those from
young controls.
Results: Flow cytometric analysis indicated that CD8+ T cells from both HIV+ and aged donors showed an
increase of approximately 2–3 fold over controls in percentage of cells producing inflammatory cytokines IFN-γ
and TNF-α . Similar analysis also revealed that the production of interleukins-4,6 and 10, production was very low
(1–2% of cells) and unchanged in these cells. Quantitative PCR also showed a substantial increase (4–5 fold) in
IFN-γ  and TNF-α  mRNA from HIV+ and aged CD8+ T cells, as did ELISA for secreted IFN-γ  and TNF-α  (2.3–4
fold). Flow cytometric analysis showed that the CD8+ CD28- T cell subset accounts for approximately 80–86%
of the IFN-γ  and TNF-α  production from the CD8+ subset in the aged and HIV+ states. The CD4+ T cell, while
not significantly changed in the HIV+ or aged states in terms of IFN-γ  production, showed a small but significant
increase in TNF-α  production in both states.
Conclusions: Our data appear compatible with physiologic conditions existing in HIV+ and aged individuals, i.e.
elevated serum levels and elevated CD8+ T cell production of IFN-γ  and TNF-α . Thus, the capacity for increased
production of cytokines IFN-γ  and TNF-α  in the aged individual by the dominant CD8+ CD28- subset may have
a profound influence on the clinical state by aggravating inflammatory pathologies such as rheumatoid arthritis,
and possibly Alzheimer's disease and Crohn's disease. In AIDS, these cytokines may contribute to wasting and
cachexia. We theorize that the predominant phenotypic change to the cytotoxic CD8+ CD28- T cell subsets in
both the HIV+ and the aged states may reflect a natural "endpoint" in CD8+ T cell differentiation induced after a
lifetime of immune activity (toward viruses, etc) in the aged, and after a massive accelerated response to HIV in
the HIV-positive individual.
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Introduction
Elderly people show an increased incidence of infectious,
neoplastic and inflammatory diseases that may be linked
to declining functional competence of the peripheral T
cells [1–5]. At the cellular level, this decline in immune
response is reflected in aged T cell in vitro proliferation,
decreased production of interleukin-2 [2,6–8] and 11–2
receptor [7,9,10], and defective progression thought the
cell cycle [11,12]. HIV+ infection likewise induces a pro-
gressive suppression in proliferation of both CD4+ and
CD8+ T cells in vitro that correlates with clinical severity,
as well as diminished 11–2 production [13–16]. Howev-
er, even stronger parallels exist between immune phe-
nomena in aging and AIDS than suppression of T cell
proliferation and 11–2 production. There is a relative in-
crease in the memory cell repertoire [17–20], and an in-
crease in absolute counts in the CD8+ CD28-populations
in both aged [22] and HIV+ donors [22–25]. The CD8+
CD28- T cell in the HIV+ state appears to be the major cy-
totoxic T cell (CTL) [26], but curiously, has shortened
telemer lengths as well [27].
Previous studies indicate considerable inconsistency re-
garding production of the immune regulatory cytokine,
interferon-γ  (IFN-γ ) and the preinflammatory cytokine,
tumor necrosis factor-α  (TNF-α ) from T cells of HFV+
and aged individuals. The disparity in IFN-γ  expression
is reflected in reports of decreased [28–31], normal
[21,32] or increased [33–37] synthesis in both aged and
HIV+ T cells. Similarly, with TNF-α , there are contradic-
tory reports of decreased [37,38], normal [29], or in-
creased [12,31,39,40] production in the HIV+ and aged T
cells. Explanations for the divergent findings can be at-
tributed to many factors including cell preparation,
choice of activators, and quantitative methodology. Re-
cently, we showed [25] that IFN-γ  production in HIV+-
derived CD8+ T cells was strongly stimulated by upon ac-
tivation anti-CD3 and PMA. Using this mode of activa-
tion, we selected flow cytometry for analysis of HIV+ and
aged T cells in this study since this method obviates the
inherent complications association with experimental
variability of T cell purification and activation. Subse-
quently, the flow cytometric data, based on the percent-
age of active cells, was supported by cytokine mRNA and
ELISA data. We find by all three methods that IFN-γ  and
TNF-α  production is enhanced several fold in CD8+ T
cells from aged and HIV+ individuals, and it is the CD8+
CD28- subset, as shown by flow cytometry, which is pri-
marily responsible. These findings assume clinical im-
portance since they may explain in part the chronic and
autoimmune pathologies in the elderly, particularly
rheumatoid arthritis, Crohn's disease, sepsis, and myel-
odysplastic syndromes, which are exacerbated by the in-
flammatory cytokines IFN-γ  and TNF-α  [41]. Likewise,
the elevation of these cytokines, particularly TNF-α  po-
tentially may contribute to the deterioration in the HIV+
or AIDS patient by promoting wasting and cachexia [42].
Results
Enhanced IFN-γ  and TNF-α  production in aged and HIV+ 
CD8+ T cells
Representative examples of the cytometric profile of
aged and HIV+ human T cells (CD4+ and CD8+ and con-
trols (normal young donors) are shown in Fig. 1; the cells
producing IFN-γ  and TNF-α  appear in the upper quad-
rants. The percentages of either CD4+ or CD8+ T cells
producing cytokine (upper quadrant) are shown. In
these studies, the peripheral blood mononuclear cells
(PBMC) were prepared and activated for 15 hrs with anti-
CD3 (plus PMA) and processed with the appropriate flu-
orescent-labeled antibodies. For 3 color FC analysis, the
samples were first gated for the CD3 positive cells thus
eliminating B cells, NK cells and macrophages, and then
examined for CD8+ and cytokine-containing cells. Based
on past studies, the non CD8+ T cells are primarily com-
posed of CD4+ T cells and are designated as such. Con-
trols (not shown) for every sample were also examined
for cytokine-producing cells (upper quadrants) in which
no activators were added; 0.0–0.6% positive cells were
observed. Previously we found [25] that activation by
anti-CD3 and PMA was far superior to other activation
modes such as Con A plus PMA in stimulating IFN-γ  syn-
thesis. Anti-CD3 or PMA alone did not induce cytokine
production [25]. In all instances with anti-CD28 as coac-
tivator, the IFN-γ  and TNF-α  responses were low, rarely
exceeding 15% of that produced by PMA/anti-CD3 acti-
vation.
The production of IFN-γ  and TNF-α  from aged and HIV+
T cells (CD4+ and CD8+) activated by anti-CD3 and PMA
is shown in Table 1I. The data were derived from the flow
cytometric analysis of the CD8+ and CD4+ T cell profiles
of forty aged, thirty-two HIV+ and forty-eight normal
young donors. Experiments with the HrV+-derived cells
were performed separately from those with aged cells
with 24 control donors used in each case. The cytokine
analysis relies on the intracellular accumulation of cy-
tokines in the Golgi compartment over the 15 hr. activa-
tion period induced by either brefeldin A or monensin.
Both inhibitors block Golgi function and thus cytokine
secretion, the former by inhibition of protein vesicle
transport [43], the latter by inhibition of Na+ gradients
[44].
Flow cytometric analysis of cells from the aged donors
activated by anti-CD3 and PMA shows that IFN-γ  pro-
duction is enhanced significantly (approximately 3 fold)
in the CD8+ T cell compartment, in terms of percent of
producing cells, compared to young control donors (Ta-
ble 1I). Even with Con A and PMA activation, the agedBMC Immunology 2001, 2:10 http://www.biomedcentral.com/1471-2172/2/10
CD8+ T cell response was 4 fold enhanced over young
controls (28.0% and 7.0% respectively)(data not shown).
The response of brefeldin-treated CD8+ cells was some-
what greater than in the monensin-treated cells, for both
aged and controls. For the HiV+ group, the number of
IFN-γ  producing CD8+ T cells was similarly enhanced
over normal controls with both types of Golgi inhibitors.
Interestingly, although the CD4+ T cell is a target for the
HIV, the IFN-γ  response is not significantly changed
from the normal CD4+ T cell response. Likewise, with the
aged CD4+ cells, there is no significant difference with
the responses of the cells from young donors.
The changes in TNF-α  production in CD8+ T cells from
HIV+ and aged individuals are comparable to that for
IFN-γ  production (Fig. 1 and Table 1I). Aged CD8+ T cells
show a significant increase (approximately 3 fold) over
young cells in the percentage producing TNF-α  (57.6 ver-
sus 19.0%). In the HIV+ cases also, the CD8+ T cells show
significantly enhanced TNF-α  production (2 fold). How-
ever, in contrast to the IFN-γ  data, the aged CD4+ T cells
are modestly, but significantly increased over the young
CD4+ T cells (50.3 versus 35.9%). The CD4+ T cells from
HIV+ donors also are slightly more capable of TNF-α
production than the normal CD4+ T cells (51.0 versus
42.0%), a difference that is significant. Thus in the aging
and HIV+ scenario, it is apparent that the CD8+ T cells
show an enhanced capacity for both TNF-α  production
and IFN-γ  production. The CD4+ T cells show a small but
significant capacity for TNF-α  production in both sce-
narios.
Comparative analysis of the CD8+ CD28- and CD8+ 
CD28+ T cells by flow cytometry
For each blood sample, a non-activated control was pre-
pared in which the PBMC were incubated in the absence
of activators (anti-CD3 and PMA), and then examined by
flow cytometry. Such controls showed no significant cy-
tokine-containing cells, and these samples were used to
calculate the resting CD4+/CD8+ distribution and the
CD28+/CD28- distribution. As shown in Table 3III,
there is a dramatic phenotypic change in the CD8+ sub-
sets in the aged and HIV states in relation to young
healthy controls. In our IFN-γ  studies, the CD28- popu-
lation accounts for 61.3% (aged) to 70.0% (HIV+) of the
total CD8+ population. In healthy controls, the CD8+
CD28- subset accounts for only 28–31% of the CD8+
cells. In the TNF-α  studies, the CD28- cells are 64.2%
(aged) to 68.3% (HIV+) of the total CD8+ population.
The TNF-α  and IFN-γ  studies were carried out separate-
ly. These results indicate that in the HIV+ and aged
states, the CD28- subset becomes dominant, assuming
approximately two-thirds of the total CD8+ cells whereas
in the normal healthy state the CD28+ T cell subset ac-
counts for approximately two-thirds. Thus, in terms of
cell numbers, the CD28- cells constitute the majority of
the CD8+ T cells and explains our previous findings
(16,45) that the mitogenic signal arising from coactiva-
tion by anti-CD28 was greatly suppressed in CD8+ T cells
from HIV+ donors compared to normal donors.
The data (Table 3III) show that the CD8+ CD28- T cells
also account for the increased production of TNF-α  and
IFN-γ  in both the HIV+ and aged states. In these states,
the percent of CD28- cells producing each cytokine dom-
inates the normal young controls by a 2:1 to 3:1 margin.
Thus not only are the CD28- cells greater in number, but
they are proportionately much more active in cytokine
Figure 1
The distribution of CD4+ and CD4+ T cells are shown for
typical samples of PBMC from HIV, aged and normal (con-
trol) donors as evaluated by flow cytometry. The cells posi-
tive for IFN-γ  (PE) or TNF-α  (PE) distribute vertically above
the horizontal marker; the vertical distance is a relative
measure of cytokine intensity. The two populations of cells
that comprise the CD3 positive population are the CD8+ T
cells and the CD4+ T cells (CD3+, CD8-) as shown on the X
axis. The percentage of CD4+ or CD8+ T cells which contain
cytokine are shown in the upper quadrants. The PBMC were
activated for 15 hrs with anti-CD3 and PMA and subse-
quently treated as described in METHODS. In all cases, non-
activated controls (not shown) were examined; less than
0.5% of cells were cytokine positive.BMC Immunology 2001, 2:10 http://www.biomedcentral.com/1471-2172/2/10
Table I: Percentage of T cell subsets Producing Cytokines
Incubated with:
Monensin Brefeldin Brefeldin
Aged IFN-γ TNF-α IFN-γ
CD4+ 16.5 ± 7.1 50.3 ± 12.6 16.6 ± 6.4
(N.S.) (p < 0.001) (N.S.)
CD8+ 42.2 ± 15.6 57.6 ± 14.3 57.2 ± 12.6
(p < 0.001) (p < 0.001) (p < 0.001)
Control1
CD4+ 14.2 ± 5.8 35.9 ± 11.2 15.8 ± 4.8
CD8+ 13.1 ± 3.5 19.0 ± 6.5 17.9 ± 4.7
HIV+
CD4+ 12.7 ± 5.1 51.0 ± 14.9 14.6 ± 6.2
(N.S.) (p < 0.01) (N.S.)
CD8+ 40.6 ± 16.5 35.8 ± 14.5 42.3 ± 11.4
(p < 0.001) (p < 0.001) (p < 0.001)
Control1
CD4+ 14.5 ± 3.6 41.9 ± 9.8 16.2 ± 4.9
CD8+ 16.1 ± 4.7 16.1 ± 8.5 13.5 ± 6.7
The percentage of CD4+ or CD8+ T cells that show a positive production of IFN-γ  or TNF-α  was determined by the number of cells above the 
anchor gate (cytokine producing) over the total cell number as described in Methods. The results are from 40 aged, 32 HIV+ and 48 normal donors; 
and show the mean ± S.D. The data obtained with the aged and HIV+-derived T cells represent experimental sets performed at different times with 
the same or different control donors (24 controls with each group). In all cases, PBMC were incubated for 15 hrs at 37° with PMA and anti-CD3 
and either monensin or brefeldin as described in Methods prior to analysis by the flow cytometry. The p values were calculated with the Student's 
t test and refers to a statistical comparison of the aged or HIV+ CD8+ T cells and the control cells. 1Controls are young donors with no known 
medical conditions or diseases. No HIV+ or aged subject was part of the control group in this study.
Table II: Comparison of cytokine Production in CD8+ CD28 and CD8+ CD28+ T cells
Cells derived form
HIV+ Control Aged Control
In TNF-α  studies
% CD28- of the 68.3 36.3 64.2 27.1
total CD8+ cells
% CD28- 55.2 26.8 68.0 29.5
producing TNF-α
% Total TNF-α± 79.5 20.5 84.6 15.4
In IFN-γ  studies
% CD28- of the total 70.0 30.7 61.3 28.0
CD8+ cells
% CD28- producing 59.8 21.2 62.3 35.1
IFN-γ
% Total IFN-γ  ± 86.7 13.3 79.6 20.4
*Analysis of CD8+ T cells from CD28+ and CD28- subsets in terms of cytokine production was performed by flow cytometry as described in Meth-
ods. Twenty HIV+ and aged donors and fifteen control donors were used in the IFN-γ  studies; twenty-two and nineteen were used respectively in 
the TNF-α  studies. ± The percent total of TNF-α  or IFN-γ  refers to the percentage of CD28- cells producing cytokine compared to the total pro-
duced by the controls and HIV+ (or aged) CD28- T cells. For example, in the TNF-α  studies, 8% of the control CD28- cells produce cytokine (27.1 
×  29.5), whereas in the aged state, CD28- cells producing TNF-α  is 43.7% (64.2 ×  68.0). Thus the TNF-α  produced by aged CD28- CD84 T cells is 
84.6% compared to 15.4% for controls.BMC Immunology 2001, 2:10 http://www.biomedcentral.com/1471-2172/2/10
production. As a consequence, the data show that the
CD28- population accounts for the majority of the cy-
tokine-producing CD8+ T cells (79.6–86.7%) in the HIV+
and aged populations. Typical examples of the CD8+
CD28- profiles are shown in Fig. 2. It is evident that the
cells from the HIV+ and aged states have a greater capac-
ity for TNF-α  and IFN-γ  production compared to the nor-
mal control CD28- or CD28+ population.
Production of other cytokines (I1-2, 4, 6 and 10)
The ability of CD4+ and CD8+ T cells from aged and
HIV+ donors to synthesize 11–2, 11–4, 11–6 and 11–10
were also studied by flow cytometry. Only in the case of
11–2 was an appreciable number of cytokine-producing
cells observed [25]. For normal young cells at least 15–
30% of CD4+ cells were positive for 11–2 while only 3–
6% of the CD8+ cells were positive. With HIV+ and aged
T cells, there was a significant 11–2 response also, but it
was generally smaller than from the young normal con-
trol cells (data not shown). The percentage of cells posi-
tive for production of 11–4, 11–6 and 11–10 was
extremely low. The number of productive cells was often
<1% and only rarely exceeded 2% of either the CD4+ or
CD8+ population. No significant difference was observed
between the control cells and those derived from HIV+ or
aged donors.
Production of IFN-γ  and TNF-α  mRNA determined by 
Quantitative PCR
The mRNA isolated from CD8+ T cells from 12 aged, 10
HIV+ and 15 controls were purified and used in these
studies. The results, shown in Fig 3 are expressed as IFN-
γ  (or TNF-α ) cDNA copies/ug total RNA. CD8+ T cells
were incubated for 3 hrs with PMA and anti-CD3 prior to
total RNA extraction. For IFN-γ , CD8+ T cells from both
the HIV+ and aged states show a 4.5–5 fold enhancement
in cDNA copies (32,000 and 47,000 respectively versus
controls of 7,400 and 9,100). Likewise, the TNF-α  cDNA
copies are enhanced approximately 4 fold in the CD8+ T
cells from aged and HIV+ states. In view of the flow cyto-
metric data, we can infer that the enhanced mRNA in the
CD8+ T cells derives primarily from the CD8+ CD28- T
cells.
Secreted IFN-γ  and TNF-α  determined by ELISA
The PBMC and purified CD8+ T cells from eight donors
and seven control donors were incubated for 66 hrs, and
the media examined by ELISA. The results, shown in Ta-
ble 3III, demonstrate that production of IFN-γ  is upreg-
ulated over controls, from 3.5–4 fold, for the CD8+ T
cells from HIV+ and aged donors. For TNF-α , the in-
crease was also substantial, 2.3–4 fold.
Discussion
Our data show that the HIV+ and aged conditions foster
a change in the CD8+ T cell repertoire characterized by
expansion of a CD8+ CD28- phenotype capable of
enhanced IFN-γ  and TNF-α  production. These results
contrast with other studies concluding that the produc-
tion of these cytokines was downregulated or unchanged
in T cells from HIV+ and aged individuals [21,28–
32,37,38]. Reliability in our findings derives from use of
flow cytometric analysis which measures de novo syn-
thesis per cell and thus obviates numerous artifacts pos-
sibly associated with ELISA or procedures that measure
mRNA synthesis. Secondly, similar results were ob-
tained with two different inhibitors of Golgi transport.
Thirdly, of the cytokines examined, including 11–4, 11–6
and 11–10, only IFN-γ  and TNF-α  were enhanced in the
HIV+ or aged states. Fourthly, CD4+ T cells did not show
a significant change in IFN-γ  production, but did show a
small but significant increase in TNF-α  production in
aged and HIV+-derived cells. Fifthly, the mRNA and
ELISA studies support the conclusions of the flow cyto-
metric data.
Table III: Secreted IFN-γ  and TNF-α  from T Cell Culture*
Source Cells IFN-γ  (pg/ml) TNF-α  (pg/ml)
Aged PBMC 70,800 ± 8,500 (p < 0.001) 35,400 ± 6,200 (p < 0.005)
Control PBMC 20,300 ± 3,000 16,900 ± 4,100
Aged CD8+ 86,300 ± 15,600 (p < 0.001) 44,200 ± 7,800 (p < 0.005)
Control CD8+ 24,400 ± 6,200 19,400 ± 4,300
HIV+ CD8+ 121,000 ± 15,600 (p < 0.001) 57,200 ≅  11,500(p < 0.001)
Control CD8+ 27,300 ± 4,800 16,400 ± 4,900
PBMC and purified CD8+ T cells were incubated for 66 hrs. as described in Methods, and the media was tested by ELISA. The results are expressed 
in pg IFN-γ  or TNF-α  per 105 cells (mean value ± S.D.). The standard deviation is shown and the p valves, determined with Student's t test, com-
pare the IFN-γ  or TNF-α  secreted by aged or HIV+-derived cells and normal control cells. Eight different aged and HIV+ donors were used, and 
seven young control donors. In the presence of 5 mM of N-acetylcysteine, the production of both INF-γ  and TNF-α  was significantly increased in 
aged, HIV+ and control samples, generally by 1.5 to 2 fold.BMC Immunology 2001, 2:10 http://www.biomedcentral.com/1471-2172/2/10
The question arises whether or not our results have phys-
iological relevance since PMA and anti-CD3 was used to
elicit the cytokine responses we observed. The question
resolves into two parts: are TNF-α  and IFN-γ  levels in-
creased in the HIV+ and aged states, and do the CD8+ T
cells show increased production of these cytokines.
There is considerable evidence supporting both parts of
this question. Regarding part one, IFN-γ  levels are ele-
vated in the sera of HIV+ patients [45]. Serum levels of
both TNF-α  and IFN-γ  were markedly higher in HIV+ pa-
tients over controls, but varied depending on the skin
disease exhibited by the patient [46]. AIDS patients also
showed elevated TNF-α  levels in the plasma [47]. Studies
of lymphocytes from aged donors showed increase se-
rum levels of TNF-α  and IFN-γ  that correlate with upreg-
ulation of HLA-DR on CD3+-lymphocytes [48].
Regarding part two, there are many studies showing that
physiological activation of CD8+ T cells from HIV+ or
aged donors prompts increased IFN-γ  and/or TNF-α
production. HIV+ lymph nodes exhibit a large (6 fold) in-
crease in CD8+ T cells, most of which are involved in
IFN-γ  production [49]. Amison et al [50] concluded that
IFN-γ  is secreted by the CD8+ T cell in HIV+ infections.
In CD8+ T cells from African HIV+ patients, stimulated
with env peptide, both IFN-γ  and TNF-α  production
were increased over controls [52]. PBMC from the elder-
ly (almost healthy donors) showed upregulation of TNF-
α  in unstimulated cultures [52]. HLA-DR activation of
CD8+ CD57+ cells from elderly subjects strongly pro-
duced TNF-α  [48]. Lipopolysaccharide-activation of T
cells from aged donors induced higher levels of TNF-α
than controls in two separate studies [53,31]. Finally, in
HIV+ patients receiving HIV type 1 antigen, both INF-γ
and TNF-α  were significantly increased in memory T
cells activated by antigen [54].
Thus there appears to be considerable support for the en-
hanced presence of TNF-α  and INF-γ  in the HIV+ and the
aged states, and for a physiologic role of the CD8+ T cell
subset in their production. Our data shows that it is the
CD8+ CD28- cell that is primarily responsible. Why the
CD8+ CD28- subset should dominated in such apparent-
ly diverse conditions as the HIV+ and the aged states is
not known. However, the notion that similarities exist
between the HIV+ and the aged states with respect to the
CD8+ CD28- T cell has been presented previously [55]. It
has also been proposed that the CD8+ CD28- T cell in the
HIV+ state is derived from the CD8+ CD28+ cells by clon-
al expansion induced by massive antigenic stimulus
(HIV proteins) since both showed the same epitope rep-
ertoire [26]. Dolad et al [56] have shown that the CD8+
CD28- cell, not the CD8+ CD28+ cell, comprises the ma-
jor CTL activity in the HIV+ state, a finding confirmed by
Vingerhoets et al [57], who associated cytotoxic T cell ac-
tivity with the CD8+ CD28- T cell in HIV-infected sub-
jects. Thus, the CD8+ CD28- T cell assumes a crucial role
in HIV infection. Likewise in the aged state, we can spec-
ulate that chronic viral and bacterial exposure over a life-
time may induce the clonal expansion of the CD8+ CD28-
T cell.
There is evidence that the cytotoxic activity of the CD28-
cell can lyse and suppress HIV-infected cells [58,59] and
thus play a protective role in HIV infection. Perhaps in
the aged cell as well, the CD28- memory cell serves a sim-
ilar protective role against a variety of viruses. The pro-
duction of IFN-γ  and TNF-α  can result in strong anti-
viral consequences as shown with hepatitis B virus [60],
but the cytokines have a dual role since they are associat-
Figure 2
The distribution of CD8+ T cells are shown as obtained from
PBMC by four color flow cytometry using anti-CD28-PE and
anti-IFN-γ -FITC (or anti-TNF-α -FITC) as described in
METHODS. The CD28+ and CD28- cells distribute vertically
and the IFN-γ  or TNF-α  positive cells distribute horizontally
according to their intensity. The percentage of the CD8+
CD28+ or CD8+ CD28- T cells which contains cytokine are
shown in the right quadrants. Cells were activated with anti-
CD3 and PMA as described in METHODS. The controls
refers to cells from a normal young donor. The HIV+ and
aged samples were derived from typical donors.BMC Immunology 2001, 2:10 http://www.biomedcentral.com/1471-2172/2/10
ed with inflammatory activity. IFN-γ , in its defensive role
against infection, is a foremost factor in converting rest-
ing macrophages into the active state [61] where they
produce reactive oxidants [62], nitric oxide [63], TNF-α
[61], and neopterin. Not only can these factors damage
DNA and host tissues but can modulate inflammatory re-
actions [60] and stimulate apoptosis [64], a major mech-
anism leading to loss of CD4+ T cells [65]. TNF-α  also
has the capacity to perturb the clinical condition in AIDS
by strongly upregulating the transcription of the HIV ge-
nome [66]. In fact, it has been proposed [67] that AIDS
is in many ways a TNF-α  disease since this cytokine it is
a potent activator of NF-kB, and an inducer of HIV ge-
nome transcription and apoptosis in HIV-infected T
cells. Moreover, the wasting, weight loss, and cachexia
associated with AIDS has also been related to TNF-α  ac-
tivity [42]. Thus both IFN-γ  and TNF-α  have the poten-
tial for a double role in the pathogenesis associated with
AIDS i.e. antiviral and inflammatory responses.
Based on the AIDS scenario, it is reasonable to propose
that chronic viral and bacterial infections suffered by an
individual over a lifetime may lead to similar conse-
quences as those occurring in acute HIV infection, i.e.,
clonal expansion of the CD8+ CD28- subset at the ex-
pense of the CD8+ CD28- subset. The data argue that the
CD28-cell may serve as a natural endpoint in the differ-
entiation of CD8+ cells, as proposed by Effros et al [27],
where aging represents a "normal endpoint" that occurs
after many years of immune activity, while AIDS repre-
sents an accelerated endpoint due to the increase rate in
T cell formation during attempted compensation for
CD4+ loss induced by HIV. By virtue of their inflamma-
tory roles, TNF-α  and IFN-γ  likely contribute to the exac-
erbation of the inflammatory conditions associated with
the aged. For example, autoimmune diseases are more
prevalent in the aged, where certain diseases such as ar-
thritis are often associated with chronic debilitation. In-
terestingly, both IFN-γ  and TNF-α  are prominent in the
pathogenesis of autoimmune diseases in general; the
former by activation of local auto antigen presentation to
appropriate T cells, and the latter by mediation of in-
flammatory tissue damage [68]. Apparently TNF-α  plays
a central role in the chronic release of highly arthritogen-
ic II-1 [69], and thus serves as a major factor in the
pathogenesis of rheumatoid arthritis (RA) [69]. Recent
studies show that treatment with anti-TNF-α  gives sig-
nificant clinical improvement in RA [70]. Thus our find-
ings in aged individuals of a prominent CD8+ CD28- T
cell subset with enhanced ability to produce TNF-α , may
assume clinical relevance. It is logical to infer that the in-
creased susceptibility of aged individuals to rheumatoid
arthritis and other autoimmune pathologies, may be due
to increased TNF-α  (and IFN-γ ) production by the CD8+
CD28- T cell. It should be noted that the action of IFN-γ
on macrophages induces TNF-α  production [61], thus
amplifying the effects of the latter.
Although IFN-γ  production in the HIV+ individual by the
CD4+ T cells (TH1) has been emphasized [13,45,49] there
appears to be little doubt that the production of IFN-γ  by
CD8+ CD28- cells may have greater clinical relevance as
discussed above on the increased serum levels [45,46].
With TNF-α  as well, our data suggest it is likely that the
increased serum levels in AIDS [46–48] may derive in
part from increased numbers of CD8+ CD28-cells. How-
ever, TNF-α  levels could also originate from monocytes
stimulated by the enhanced IFN-γ  production. In any
case, the HIV+ state is replete with antagonistic complex-
ities of antiviral effects of IFN-γ  and TNF-α  on one hand,
and their inflammatory effects on the other. Overall, our
data presents an intriguing parallel between AIDS and
the aging state with regard to their cytokine and CD8+ T
cell profiles, and the potential for new insight into aging
mechanisms. It is noteworthy that our results are com-
Figure 3
The production of cytokine mRNA determined by quantita-
tive by PCR is shown for (A) HIV+ donor CD8+ T cells and
(B) aged donor CD8+ T cells. The cDNA copies per ug RNA
from the CD8+ T cells. The cDNA copies per ug RNA from
the CD8+ T cells were derived from: 1, nonativated controls;
2, activated controls (INF-γ ); 3, activated HIV+ or aged (INF-
γ ); 4, activated controls (TNF-α ); 5, HIV+ or aged (TNF-α ).BMC Immunology 2001, 2:10 http://www.biomedcentral.com/1471-2172/2/10
patible with recent aging studies using gene arrays to
measure gene expression in the neocortex and cerebel-
lum of aged and young mice. Lee et al [71] found that in
both brain regions, one hallmark of aging was enhanced
gene expression of the inflammatory response, including
proinflammatory peptides and many interferon-related
proteins. Thus the advent of the CD8+ CD28- cell in ag-
ing, with its potential for proinflammatory cytokines,
could have profound effects not only on autoimmune
diseases, but on Alzheimer's disease as well since cy-
tokines may contribute to the neuropathology [72].
Materials and Methods
Materials
Con A, phorbol myristate acetate (PMA), N-acetyl-
cysteine (NAC), brefeldin A and monensin were obtained
from Sigma (St. Louis, Mo.), fetal calf serum from Harlan
Bioproducts (Madison, Wis.), anti-CD28 and anti-CD3
(4E) from Research Diagnostics (Flanders, N.J.). Puri-
fied monoclonal Ab anti-CD4, anti-CD8, anti-CD 14 and
anti-CD 19, bound to magnetic beads (BioMag), were ob-
tained from Perseptive Diagnostics (Cambridge, MA).
Interleukin 4, 8, 10 and 12 were obtained from the Gen-
zyme Corp.
Study approval
This study was approved by the Institutional Review
Board of the Ponce School of Medicine, Ponce, PR.
Blood donors
The HIV+ population (32 donors aged 22–34 years,
mean 29.3 years) used in this study had a CD4+ T cell
count from 210–500 cells/mm3 and fell in the A2 and B2
classification recommended by the Centers for Disease
Control. Most (93%) of the HIV+ donors were receiving
the anti-retroviral drug zidovudine. Transmission in the
HIV+ donors was approximately 60% from intravenous
drug use and 40% from unprotected sexual activity.
Blood from forty aged individuals (mean 84.2 years,
range 76–98 years) was collected for this study. The con-
trols (48 young Hispanics aged 19–30 years, mean 23.7
years, from Ponce, Puerto Rico), had no serious medical
problems. All donors were Hispanic, blood was collected
from HIV+ individuals (Hispanic) under the direction of
Dr. Harold I. Laroche and Dr. E. Godreau, Center for Di-
agnosis and Treatment, Ponce. The aged population, re-
cruited from the retirement home Los Diamantes, had
no serious medical problems in general. Some had minor
arthritis and high blood pressure (medicated); one had
Parkinson's disease.
Purified T cells
PBMC were prepared by Hypaque-Ficoll centrifugation
of blood diluted 1:1 with PBS (5). For preparation of pu-
rified T cells (CD4+ and CD8+) free of macrophages,
granulocytes, B cells, and NK cells, the PBMC (1 ×  107
cells) were centrifuged, and diluted to 200 ul with 0.1%
BSA in PBS. After addition of 10 ul of fetal calf serum and
10 ul of antibody "mix" (T cell negative isolation kit from
Dynal Inc), the cells were incubated 10 minutes at 4°,
washed in PBS, and suspended in 900 ul PBS with 100 ul
of "depletion" beads (Dynal). After 15 minutes at room
temperature, the beads are magnetically removed leav-
ing highly purified T cells (CD4+ and CD8+, 98% purified
in general). The yield varied from 40–50% based on the
starting number of PBMC. For the preparation of puri-
fied CD4+ T cells, 2 ×  107 purified T cells were incubated
for 30 minutes on ice with BioMag mouse anti-human
CD8 (IgG1) monoclonal Ab (500 ul) in 3.0 ml RPMI plus
9% FCS (diluted 1:1) for 30 min on ice with rocking. Sim-
ilarly, to obtain purified CD8+ T cells, the same proce-
dure was followed except BioMag mouse anti-human
CD4 (IgG2a) monoclonal Ab (500 ul) was used. The cell
suspension was brought to 10 ml with cold RPMI media,
and the desired T cell subset was obtained by magnetic
removal of the contaminating cells. Flow cytometric
analysis indicated that the T cell subsets were 93–98%
purified. The yield of control and aged cells varied from
58–89% generally, whereas the yield from HIV+ blood
generally fell between 24–68%. Accessory cells were ef-
fectively removed during T cell isolation as shown by the
failure of mitogen-induced proliferation in the absence
of coactivators. All cell purification steps were completed
and assays initiated within 10 hrs. after blood donation.
The purified CD8+ T cells were used for the ELISA and
quantitative PCR studies.
Flow cytometric analysis (FC)
Prior to FC analysis, PBMC (3.3 ×  105) suspended in 600
ul media were incubated at 37°C overnight in 6% CO2
with anti-CD3 (1:500 dilution of acetates fluid) and PMA
(2.5 ng/ml) as described previously [25]. Either mon-
ensin (1 uM) or brefeldin A (1 ug/ml) was used in all cas-
es to block Golgi function and allow cytokine
accumulation with the cell. For analysis of CD4+ and
CD8+ T cells, the PBMC (activated and non activated
controls) were treated as described by the PharMingen
(Flow Cytometry and Cell Analysis Catalog (1998) "Im-
munofluorescent Staining of Intracellular Cytokines for
Flow Cytometric Analysis", pp415-417). Briefly, PBMCs
were washed twice with staining buffer (PBS plus 0.5%
bovine serum albumin), and then fixed by suspending in
cold 0.5% paraformaldehyde (PFA). After incubation for
20 min at 4°, the cells were centrifuged, decanted and re-
suspended in 4% PFA for 30 min at 4°. Cells were then
washed with 1 ml of staining buffer, and incubated 30
min at 4° with 50 ul permeabilization buffer (0.1% sa-
ponin, PBS, 0.1% azide). To the cell pellet, 3 ul of phyco-
erythrin (PE) conjugated mouse anti-human IFN-γ  or
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incubated 30 min at 4°. The cells were then washed with
1 ml permeabilization buffer, spun down, and gently re-
suspended. Then 10 ul of fluorescein isothiocyanate
(FITC) mouse anti-CD8 (Leu-2a) (Becton-Dickinson),
and 10 ul peridinin chlorophyll (PerCP) mouse anti-CD3
(Leu-4) (Becton-Dickinson) were added, followed by in-
cubation in the dark for 20 min at room temperature. Af-
ter washing with 1 ml of staining buffer, the cells were
fixed with 600 ul of 0.5% PFA for approximately 1 day
and then analyzed with a FACSCalibur flow cytometer
(Becton-Dickinson) equipped with a FL4 channel.
As an alternative to FC analysis of activated PBMC de-
scribed above, we also studied activated CD4+ and CD8+
T cells purified as described in the previous sections.
These studies we carried out in order to completely elim-
inate the possibility, however remote, that our FC proce-
dure did not discriminate between the CD8+ T cells and
NK cells, which have low density CD8+ receptors. How-
ever, our FC procedure used a sufficiently high "anchor
gate" to examine only the high density CD8+ receptors
which are uniquely characteristic of the CD8+ T cell. This
is accomplished by using an "anchor gate" which is suffi-
ciently high. As expected, our analysis of CD8+ T cells us-
ing either the purified cells or the PBMC were in
complete agreement in 5 experiments in which they were
compared, i.e., both showed the same increased produc-
tion of IFN-γ  and TNF-α  from HIV+ derived or aged
CD8+ T cells.
Analysis of CD4+ and CD8+ T cells
Four-color cytometric analysis was performed with a
Power-Macintosh 7600 computer with Cellquest soft-
ware. Statistical analysis was performed on data collect-
ed from 10,000 events (data points) per cell sample. To
distinguish t cell subsets, a gate was drawn around lym-
phocytes by forward scatter and side scatter (region 1
(R1)). T cells were identified as a CD3 (FL3) positive pop-
ulation (R2), thereby excluding CD3- populations such
as B cells, macrophages, and NK cells. In order to analyze
T cell subsets (CD4+ and CD8+ cells) for each cytokine
production, contour plots on CD8+ (FL1)/ cytokine
(FL2) of logical gate 1 events (R1 + R2) were obtained.
The event numbers and percentages of each quadrant
event were recorded. For simplicity, the CD3+ CD8- T
cell subset are assumed to be CD4+ and labeled as such
in Fig. 1. In our experience, the CD3+ CD4+ comprise
95% or more of the CD3+ CD8- T cell subset in normal
blood. In HIV+ blood, a few CD4+ T cells may be masked
by soluble gp-120, but this would not affect the CD3+
CD8+ population.
Analysis of CD28+ and CD28- T cells using four-color cy-
tometry
For this study, PBMC were treated as described above ex-
cept that anti-human CD3+ (FL4) coupled to allophyco-
cyanin (APC) was used along with anti-IFN-γ  FITC (FL1),
anti-CD28 PE (FL2) and anti-CDS PerCP (FL3). Region
1 (R1) was drawn to identify lymphocytes by forward
scatter and side scatter, and R2 was drawn to identify T
cells (FL4 positive). Logical gate 1 (R1+R2) was used to
identify CD4 (FL3 negative) and CD8 (FL3 positive) sub-
sets that were designated as R3 and R4 respectively. Log-
ical gate 2 (R1+R2+R3) events were analyzed for
cytokine production by CD28+(FL2) or CD28- subpopu-
lations by plotting two dimensional contour plots. Logi-
cal gate 3 (R1+R2+R4) events were similarly analyzed.
Competitive PCR
The competitive PCR was performed using both IFN-γ
mRNA and TNF-α  mRNA detection kits from BioSource
Corp. The mRNA was highly purified from purified CD8+
cells activated for 3 hrs, with the Ambion RNAqueous kit
for total RNA, and the Micro Poly (A) pure kit for mRNA.
Generally the mRNA obtained was near 2% of total RNA.
The cDNA was obtained by use of reverse transcriptase
(Invitrogen). PCR was performed in 100 ul final volume
containing: 1) 3 ul of IFN-γ  primer; 2) 18 ul 10X reaction
buffer; 3) 25 ul 200 uM NTP's; 4) 44.5 ul H2O; 5) 5 ul cD-
NA; 6) 5 ul Internal Calibration Standard (ICS) DNA and
0.5 ul Taq polymerase. Components were gently mixed
and centrifuged, then heated 2 min at 95°. Thirty cycles
were performed with a Perkin Elmer 9600 thermocycler
as follows: 1 min at 95°, 1 min at 55°, 1 min at 72°. The re-
action was next heated at 72° for 10 min following by
cooling at 4°. A 15 ul sample from each PCR reaction was
analyzed on 2% agarose gels containing 0.5 ug/ml ethid-
ium bromide along with molecular weight standards to
determine the fragment size. Bands were visualized un-
der UV light and photographed using Polaroid film.
After cDNA amplification, 25 ul of PCR mix was removed
and transferred to a microcenterfuge tube. The same vol-
ume of denaturation solution (alkaline pH) was added to
the tube and incubated for 10 min at room temperature.
The material was neutralized by the addition of 450 ul of
hybridization solution prior to addition to the ICS or
IFN-γ  oligonucleotide capture wells (OCW). In order to
acquire quantitative results the denatured amplicons
were analyzed at 1/20, 1/100, 1/200 dilution in hybridi-
zation buffer.
Following hybridization, unbound material was removed
by washing the wells four times with 200 ul diluted wash
buffer; 100 ul of streptavidin – HPR was then added to
each well and incubated for 30 min at room temperature.
The wells were washed again, and 100 ul of stabilizedBMC Immunology 2001, 2:10 http://www.biomedcentral.com/1471-2172/2/10
chromogen (substrate) was added. After a 30 minute in-
cubation in the dark, the reaction was stopped by addi-
tion of 100 ul stop solution and the observance was
measured at 450 nm. The optical density (OD) in each
well is proportional to the amount of amplicon present,
which can be related to the copy number of either ICS or
IFN-γ  in the original PCR reaction. The total OD is calcu-
lated as sample OD multiplied by the amplicon dilution.
The number of copies of IFN-γ  in each PCR reaction are
calculated from the ratio of total OD for the IFN-γ  specif-
ic well to the total OD for the ICS well times the and input
copies of the ICS.
ELISA
The IFN-γ  and TNF-α  secreted by CD8+ T cells into cul-
ture media was quantitated using an Elisa kit from either
BioSource (Corp.) or Research Diagnostics. The CD8+ T
cells were incubated at 37° for 66 hours in precisely the
same way as for mitogenic assay except volumes were
doubled and 50,000 cells were used. Samples were run
in duplicate, the results were highly reproducible (S.D.
<15% for any given assay) and sensitive. However, sensi-
tivity was not important since with most samples it was
necessary to dilute the culture fluid by 1:20 or more. The
procedure was followed as recommended by the manu-
facturer. The standard curves for IFN-γ  and TNF-α ,
which intersected the origin, was generally linear up to
500 pg/ml for recombinant IFN-γ  and 400 pg/ml for
TNF-α .
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